**FHIT suppresses inflammatory carcinogenic activity by inducing apoptosis in esophageal epithelial cells**

Koshi Mimori, Takehiko Yokobori, Masaki Iwatsuki, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Masaki Mori

Department of Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu and Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan

---

**Abstract**

We focused on the mechanism by which FHIT suppresses neoplastic transformation in normal but damaged esophageal epithelial cells exposed to inflammatory stimuli in vivo and to chemo-radiotherapy in clinical samples. For *in vitro* analysis, Adenoviral-FHIT (Ad-FHIT) in TE4 and TE2 were used for microarray analysis. For *in vivo* analysis, wild-type (WT) FHIT and FHIT-deficient (KO) C57BL/6 mice were exposed to N-nitrosomethylbenzylamine (NMBA) and to a cyclooxygenase-2 inhibitor (COXI). Considering DNA damage on clinical samples, expressions of FHIT, BAX and PCNA were evaluated by comparing between 3 cases of esophageal cancer cases of the chemo-radiotherapy responder and 7 cases of the non-responder. In *in vitro* analysis, we listed the down-regulated genes in Ad-FHIT that significantly control Lac-Z infected cells, such as prostaglandin E receptor 4, cyclooxygenase-1 and cyclooxygenase-2. In *in vivo* analysis, FHIT-KO mice were much more susceptible to tumorigenesis than were FHIT-WT mice. A significant difference in PGE2 activation was observed between FHIT-WT mice (5.2 ng/mL) and FHIT-KO mice (28.4 ng/mL) after exposure to NMBA in the absence of COXI as determined by ELISA assay (P<0.01). BAX expression was significantly higher in FHIT-WT (1.0±0.43) than in FHIT-KO (0.17±0.17) (P<0.05). The IHC score for FHIT and BAX expression was significantly higher in responders than the others (P<0.05).

FHIT possesses tumor suppressor activity by induction of apoptosis in damaged cells after exposure to inflammatory carcinogens and DNA damaging chemo-radiotherapy.

---

**Introduction**

Esophageal cancer, considered to be one of the most intractable human malignancies, can be initiated by several different environmental carcinogens. Pandeya *et al.* showed that alcohol intake significantly increases the risk of squamous cell carcinoma of the esophagus, and smoking modifies the effect of alcohol intake on risk.1 Continuous exposure to alcohol and smoke damages esophageal epithelial cells and accelerates malignant transformation. In addition to consumption of alcohol and exposure to myosmine in smoke, several inflammatory processes, such as gastro-duodenal reflex disease, also gave rise to esophageal cancer.2 In addition, continuous inflammation of colorectal epithelium gives rise to malignant transformation. Therefore, the presence of FHIT prevents inflammatory bowel disease-mediated cancer as we reported in our previous study.3 There are few studies of FHIT, a tumor suppressor molecule, and of the mechanism by which it suppresses the actions of inflammatory carcinogens in the esophagus.

In our previous study, we showed that fragile histidine triad (FHIT), which is located on 3p14.2 within a common fragile region, was repressed in normal esophageal epithelial cells and esophageal cancer, including esophageal cancer, due to an alternation of genomic DNA.4,5 In addition, the FHIT gene was repressed in normal esophageal epithelium in healthy individuals who were exposed to large amounts of alcohol and tobacco smoke.6 We hypothesized that continuous inflammatory stimulation of epithelial cells might play a causative role in carcinogenic activity. Therefore, we examined the role of FHIT protein and the severe inflammatory cascade that occurs in FHIT-deficient bone marrow-transplanted mice exposed to excessive inflammatory stimuli. FHIT-deficient bone marrow-transplanted mice exhibited neoplastic alterations, including accumulation of DNA damage. Those carcinogenic stimuli allowed long-term survival of genotoxin-exposed FHIT-deficient hematopoietic stem cells with deleterious mutations.

Therefore, in the current *in vivo* study, we show that FHIT-deficient esophageal epithelial cells with enhanced carcinogenic potential might develop into tumors due to the PGE2-mediated inflammatory cascade. In addition, to determine the role of FHIT in human esophageal cancer, we asked whether FHIT activated esophageal cancer can induce apoptosis following cellular insults, such as chemo-radiotherapy treatment.
Materials and Methods

Microarray analysis in esophageal cancer cells after the administration of adenoviral FHIT

We previously reported the expression of genes following adenoviral attenuation of FHIT.\(^{1,12}\) In the current study, we established a gene expression profile, focusing on the PGE2 synthetic pathway following adenoviral-induced expression of FHIT. As shown in Table 1A, in order to improve the reliability of the expression profile of adenoviral-FHIT compared with adenoviral-lacZ vector, we performed 7 repetitive hybridizations among three cancer cell lines lacking endogenous FHIT expression: TE4 and TE2 (esophageal cancer, provided by Dr. Y Shimada, Department of Surgery and Basic Surgical Research, Kyoto University).\(^{1,13}\)

Total RNAs were extracted and 2.5 µg aliquots of mRNA from either Ad-FHIT or control infected samples were labeled with Cy3-dCTP or Cy5-dCTP (Amersham, Biotech). Labeled probes were hybridized for 14-16 hr at 65°C with a chip, a total number of 7 times altogether. The chip was printed with 38384 genes following adenoviral attenuation of FHIT.\(^{13,14}\) In the current study, we established a synthetic pathway following adenoviral-FHIT expression: TE4 and TE2 (esophageal cancer cells after the administration of both reagents concomitantly for eight weeks. All mice were sacrificed 4 days before NMBA (6 mg/L), and the administration of COXI (40 mg/L) was started four days before NMBA (6 mg/L), and the administration of both reagents continued for eight weeks. All mice were sacrificed to excise the forestomach which was fixed in buffered formalin and prepared for hematoxylin and eosin (H&E) staining and immunohistochemistry. A part of the epithelium in each tissue was dissected from the remaining tissues (using a blade to strip off the connective tissue layer), snap frozen in liquid nitrogen and stored in -80°C for the PGE2 assay.

Carcinogenicity study

Eight to ten week old male mice with a wild-type or FHIT-deficient genotype in a C57BL/6 background were divided into four experimental groups: i) 7 wild-type mice were given N-nitrosomethylbenzylamine (NMBA);\(^{16}\) ii) 6 FHIT-deficient mice were given NMBA; iii) 7 wild-type mice were given both NMBA and cyclooxygenase-2 inhibitor, celecoxib (COXI);\(^{17}\) iv) 6 FHIT-deficient mice were given both NMBA and COXI. For the NMBA group, NMBA was administered by drinking water (6 mg/L) for eight weeks. For the NMBA plus COXI group, the administration of COXI (40 mg/L) was started four days before NMBA (6 mg/L), and the administration of both reagents continued for eight weeks. All mice were sacrificed to excise the forestomach which was fixed in buffered formalin and prepared for hematoxylin and eosin (H&E) staining and immunohistochemistry. A part of the epithelium in each tissue was dissected from the remaining tissues (using a blade to strip off the connective tissue layer), snap frozen in liquid nitrogen and stored in -80°C for the PGE2 assay.

Immunohistochemical study

We performed immunohistochemical studies of 26 specimens from the forestomach epithelium from mice, and 10 representative lesions from 10 patients with esophageal cancer. 4 µm sections were prepared for tissue slides. We incubated slides with primary rabbit Fhit antiserum against the C terminus of the Fhit protein (1:1,000 dilution, overnight, Zymed), BAX (2772, Cell Signaling; N-20, Santa Cruz), COX2 and PCNA antisera, followed by incubation with appropriate biotinylated secondary antibodies.

Slides were then incubated with streptavidin horseradish peroxidase (Dako; 1:10,000 dilution). Sections of normal tissue were used as a reference control for staining and scoring. The intensity of expression of Fhit, BAX and PCNA was scored (as described previously) as follows: 0, no staining; 1+, less staining than normal epithelium; 2+, similar to normal epithelium; 3+, stronger than normal epithelium.

Table 1A. Combinations of adenoviral vectors and Cy3-dCTP or Cy5-dCTP in four trials.

<table>
<thead>
<tr>
<th>Experiment</th>
<th>Cell lines</th>
<th>Labeled vectors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TE4</td>
<td>Ad-lac Z</td>
</tr>
<tr>
<td>#2</td>
<td>TE4</td>
<td>Ad-lac Z</td>
</tr>
<tr>
<td>#3</td>
<td>TE2</td>
<td>Ad-lac Z</td>
</tr>
<tr>
<td>#4</td>
<td>TE2</td>
<td>Ad-lac Z</td>
</tr>
</tbody>
</table>


Table 1B. Genes commonly down-regulated in Adenoviral-FHIT cells compared to Adenoviral-lacZ by random permutation test of four trials.

<table>
<thead>
<tr>
<th>No.</th>
<th>Symbol</th>
<th>Accession</th>
<th>Title (chromosomal location)</th>
<th>Function</th>
<th>Expression ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>EPHR</td>
<td>N28920</td>
<td>Prostaglandin E</td>
<td>Receptor for prostaglandin E(5p13.1)</td>
<td>0.78(0.45-0.94)</td>
<td>0.025</td>
</tr>
<tr>
<td>2</td>
<td>COXI-1</td>
<td>R96180</td>
<td>Cyclooxygenase-1</td>
<td>Synthesis of prostaglandin G(9q32-q33.3)</td>
<td>0.85(0.58-1.23)</td>
<td>0.006</td>
</tr>
<tr>
<td>3</td>
<td>SLC21</td>
<td>H67372</td>
<td>Solute carrier family 21</td>
<td>Prostaglandin transporter (13q21)</td>
<td>0.85(0.75-1.03)</td>
<td>0.038</td>
</tr>
<tr>
<td>4</td>
<td>EGR-1</td>
<td>H42051</td>
<td>Early growth response-1</td>
<td>Activating the transcription (5q31.1)</td>
<td>0.86(0.53-1.28)</td>
<td>0.022</td>
</tr>
<tr>
<td>5</td>
<td>ILIB</td>
<td>W47101</td>
<td>Interleukin 1-Beta</td>
<td>Stimulate prostaglandin (2q14)</td>
<td>0.87(0.53-1.07)</td>
<td>0.041</td>
</tr>
<tr>
<td>6</td>
<td>COX-2</td>
<td>R80217</td>
<td>Cyclooxygenase-2</td>
<td>Synthesis of prostaglandin E(1q25.2-q25.3)</td>
<td>0.91(0.58-1.41)</td>
<td>0.032</td>
</tr>
</tbody>
</table>

**Table 2. Comparison of expression of Fhit, Bax and PCNA between responsive lesions and non-responsive lesions in esophageal tumors after chemoradiotherapy.**

<table>
<thead>
<tr>
<th>n</th>
<th>Fhit</th>
<th>Bax</th>
<th>PCNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>2.33±0.578</td>
<td>2.67±0.58</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
<td>0.14±0.38</td>
<td>3</td>
</tr>
</tbody>
</table>

Fhit and Bax showed statistically significant differences (P<0.001, R=4.44)
Results
Down-regulated gene profiles in the PGE2 synthetic pathway in adenoviral-FHIT transduced cancer cells

In Table 1B, we analyzed up-regulated genes in the PGE2 synthetic pathway in apoptotic cells in which adenovirus attenuated FHIT. We found a statistically significant lower expression of cyclooxygenase-2 (COX-2) in adenoviral-FHIT cells than control cells (P=0.032). In addition, other molecules related to the synthesis of PGE2 were significantly reduced by up-regulated expression of FHIT in cancer cells, including COX-1 (P=0.006), early growth response-1 (P=0.022), and PGE receptor 4 (P=0.025). Therefore, FHIT should not inactivate PGE2 synthetic pathway genes directly and specifically; thus, FHIT might inactivate any biological activity in any cancer cells. Note also that adenoviral-FHIT transduction induced more apoptosis in TE4 cells than in TE2, and that expression of the above mentioned genes was much lower in apoptotic TE4 cells than in non-apoptotic cell TE2 cells (data not shown).

Activation of PGE2 in the forestomach of mice without a COX inhibitor

Among the four groups subjected to NMBA exposure (wild-type mice, wild-type mice with COXI, FHIT-deficient mice and FHIT-deficient mice with COXI), a significant difference was observed in PGE2 production between FHIT wild-type mice (5.2 ng/mL) and FHIT-deficient mice (28.4 ng/mL) without COXI by ELISA assay (P<0.01) (Figure 1). In other words, PGE2 was significantly more abundant in FHIT-deficient mice than in wild-type FHIT mice. On the other hand, the simultaneous administration of NMBA and COXI eliminated the significant difference in PGE2 level in the forestomach between animals with and without FHIT.

In the immunohistochemical analyses of the four groups, BAX expression in FHIT wild-type mice scored significantly higher than in FHIT-deficient mice (P<0.047). There was no significant difference in COX2 expression between FHIT wild-type mice and FHIT-deficient mice (Figure 1). PCNA expression was higher in FHIT-deficient mice than in FHIT wild-type mice in spite of the administration of COXI; however, there was no statistically significant difference between them.

Chemo-radiotherapy responsive lesions in esophageal cancer revealed expression of FHIT and BAX

Before comparing the expression of FHIT, BAX, and PCNA in esophageal tumors after chemo-radiotherapy, it was important to deal with the tumors’ variable responsiveness to therapy. Therefore, we hypothesized that it would be helpful to separate the responsive and non-responsive tumors into two groups. Thus, we compared expression of FHIT, BAX and PCNA between responsive lesions and non-responsive lesions in esophageal tumors after chemo-radiotherapy (Table 2). The IHC score of FHIT expression was 2.33±0.578 in the 3 responsive lesions, while there was no FHIT expression in the 7 non-responsive lesions (P<0.05). As for BAX expression, 3 responsive lesions scored significantly higher (2.67±0.58) than 7 non-responsive lesions (0.14±0.38) (P<0.05). PCNA expression in 7 non-responsive lesions was three times higher than in 3 responsive lesions; however, there was no statistically significant difference between them. Those findings are demonstrated in 4 cases in Figure 2. In cases #1 and 3, non-responsive lesions showed robust expression of PCNA; however, neither FHIT nor BAX was observed in these identical cases. On the other hand, in cases #2 and 9, chemo-radiotherapy-responsive lesions with necrotic tissues showed FHIT and BAX expression, while PCNA expression was weak.

Figure 1. Comparison of prostaglandin E2 (PGE2) levels and expression of fragile histidine triad (FHIT), BAX, and proliferating cell nuclear antigen (PCNA) proteins among FHIT wild-type mice and FHIT–deficient mice. Mice with C57BL/6 backgrounds were divided into four experimental groups. (1) Seven wild-type mice given N-nitrosomethylbenzylamine (NMBA) [first lane]. (2) Six FHIT-deficient mice given NMBA [second lane]. (3) Seven wild-type mice given both NMBA and the cyclooxygenase-2 inhibitor, celecoxib (COXI) [third lane]. (4) Six FHIT-deficient mice given both NMBA and COXI [fourth lane]. The upper row indicates the production level of PGE2 assayed by ELISA (ng/mL). The lower three rows demonstrate expression levels of three proteins, FHIT, BAX, and PCNA among the four groups.
Discussion

In the current study, we demonstrated that esophageal epithelial cells from FHIT-deficient mice increased their production of PGE₂ and reduced the frequency of apoptosis in vivo following exposure to NMBA. Considering this evidence, we conclude that FHIT promotes apoptosis in normal but damaged epithelial cells by the inflammatory stimuli as well as in damaged carcinoma cells in the esophagus by the chemo-radiotherapy. After exposure to cellular damage, NMBA in vivo and chemo-radiotherapy during therapeutic treatment, we speculated that the number of surviving cells with the capacity for malignant transformation increases and therefore PGE₂ production derived from those non-apoptotic malignant cells increases accordingly.

In our previous study, we reported a direct correlation between PGE₂ synthesis and FHIT expression in colorectal cancer cells, suggesting that FHIT’s postulated tumor suppressive effect operates through PGE₂, but not COX-2 according to our immunohistochemical data. We concluded that FHIT protein did not inhibit a specific molecule in the arachidonic acid cascade, but directly and specifically PGE₂ activity. On the other hand in esophageal cancer according to the expressing genes’ profile in Adeno-FHIT attenuated cells rather than controls, we found downregulation of whole pro-inflammatory molecules in the arachidonic acid pathway, such as PGE₂, COX-1, COX-2 and receptors for PGE₂. We assumed that FHIT induces apoptosis in cells damaged by inflammatory carcinogens; therefore, total PGE₂ production and synthetic pathway molecules are presumably reduced in FHIT-expressing apoptotic cells. In esophageal cancer, FHIT does not work as a mere anti-inflammatory molecule, but induces apoptosis buffering the cellular DNA damage by strong inflammatory stimuli leading to malignancies.

As for the chemo-radiotherapy damaged esophageal cancer tissues, FHIT induced apoptosis of damaged esophageal cancer cells as a response to the chemo-radiotherapy, regardless of absence of local inflammation in esophageal cancer tissues. In other words, the absence of FHIT protein in each case mostly due to the genetic alteration in 3p14 locus, a fragile site, might not be able to induce apoptosis nor response to the chemo-radiotherapy in cancer tissues regardless of the presence of inflammation.

In conclusion, we demonstrate here that FHIT might not directly affect specific molecules regulating the PGE₂ synthetic pathway, but might instead inactivate whole damaged cells and thereby decrease the amount of metabolic products by inducing apoptosis after exposure to the DNA damaging inflammatory carcinogens and to DNA damaging chemo-radiotherapy.

References